# Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema

> **NCT00375713** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 466 (actual)

## Conditions studied

- Dermatitis
- Eczema

## Interventions

- **DRUG:** Levocetirizine
- **DRUG:** Cetirizine
- **DRUG:** Placebo-Levocetirizine
- **DRUG:** Placebo-Cetirizine
- **DRUG:** Standard topical steroid (1% hydrocortisone) ointment

## Key facts

- **NCT ID:** NCT00375713
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2011-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00375713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00375713, "Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00375713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*